Akebia expects to file vadadustat again to FDA by end of Q3; Societal CDMO seeks to secure 8M+ in latest raise
Akebia now expects to refile its chronic kidney disease treatment vadadustat by the end of September.
The biotech said Thursday morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
